Acute Myeloid Leukemia Clinical Trials

1810 clinical trials for Acute Myeloid Leukemia across international registries, including 373 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India — RECRUITING · PHASE4
• IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. — RECRUITING · PHASE3
• A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) — RECRUITING · PHASE1
• A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of L Annamycin for Injection in Combination with Cytarabine Injection Versus Placebo in Combination with Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects with Refractory/Relapsed Acute Myeloid Leukemia — RECRUITING · PHASE3
• A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) — RECRUITING · PHASE2
• PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS — RECRUITING · PHASE1
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) — RECRUITING · PHASE2
• Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia — RECRUITING · PHASE2
• Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation — RECRUITING
• Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) — RECRUITING · PHASE2
• Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients — RECRUITING
• Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) — RECRUITING · PHASE2
• FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia — RECRUITING · PHASE1
• A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) — RECRUITING · PHASE1
• Niclosamide in Pediatric Patients With Relapsed and Refractory AML — RECRUITING · PHASE1
• Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms — RECRUITING · NA
• Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT) — RECRUITING · NA
• Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) — RECRUITING · PHASE2
• Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation — RECRUITING · PHASE2
• Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS — RECRUITING · PHASE2
• Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) — RECRUITING · PHASE2
• Phase I Study of HC-7366 for Acute Myeloid Leukemia — RECRUITING · PHASE1
• Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome — RECRUITING · PHASE2
• Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances — RECRUITING · PHASE1
• HOVON 173 AML: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy — RECRUITING · PHASE3
• Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) — RECRUITING · PHASE2
• Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 — RECRUITING · PHASE3
• Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis — RECRUITING
• Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) — RECRUITING · PHASE3
• Venetoclax Combined With Azacitidine for Consolidation Therapy in AML — RECRUITING · PHASE2
• VA Consolidation in Intermediate-Risk AML — RECRUITING · PHASE2
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection — RECRUITING
• A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. — RECRUITING · PHASE1
• First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) — RECRUITING · PHASE1
• Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML) — RECRUITING · PHASE2
• A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia — RECRUITING · PHASE2
• 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome — RECRUITING · PHASE1
• A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia — RECRUITING · PHASE1
• Study of SA+X in the Treatment of Newly Diagnosed AML — RECRUITING · PHASE2
• A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) — RECRUITING · PHASE1
• A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations — RECRUITING · PHASE3
• A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) — RECRUITING · PHASE2
• A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant — RECRUITING · PHASE1
• Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML — RECRUITING · PHASE3
• CIML NK Cells With Venetoclax for AML — RECRUITING · PHASE1
• Motixafortide for MRD Sensitization in AML — RECRUITING · PHASE2
• A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia — RECRUITING
• ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia — RECRUITING · NA
• A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (QuANTUM-Wild) — RECRUITING · PHASE3
• Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors — RECRUITING · PHASE1

Refine this search